Increased cyclin D1 expression in chronic pancreatitis

Pancreas

Volumn 17, Issue 2, 1998, Pages 158-162

  Kornmann, Marko ^c   Ishiwata, Toshiyuki ^c   Arber, Nadir ^a   Beger, Hans G ^b   Korc, Murray ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic pancreatitis; Cyclin D1

Indexed keywords

CYCLIN D1;

ACINAR CELL; ADULT; ARTICLE; CELL CYCLE G1 PHASE; CELL DEGENERATION; CELL DENSITY; CHRONIC PANCREATITIS; FEMALE; HUMAN; HUMAN TISSUE; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031868407     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199808000-00008     Document Type: Article

References (31)

1. Pines J. Protein kinases and cell cycle control. Semin Cell Biol 1994;5:399-408.
2. Sherr CJ. G1 phase progression: cyclin on cue. Cell 1994; 79:551-5.
3. 1 events and regulation of cell proliferation. Science 1989;246:603-8.
4. Jiang W, Kahn SM, Zhou P, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 1993;8:3447-57.
5. Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993;7:1559-71.
6. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994;14:1669-79.
7. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993;7:812-21.
8. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumor cell lines. Oncogene 1994;9:707-18.
9. Tam SW Theodoras AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with CDK4 is required for cyclin D1 function in G1 progression. Oncogene 1994;9:2663-74.
10. Zhou P, Jiang W, Zhang Y-J, et al. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 1995;11:571-80.
11. Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signaling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 1996;16:6917-25.
12. Schrump DS, Chen A, Consoli U. Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther 1996;3:131-5.
13. Arber N, Doki Y, Han EK-H, et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 1997;57:1569-74.
14. Motokura T, Arnold A. Cyclins and oncogenesis. Biochim Biophys Acta 1993;1155:63-78.
15. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
16. McIntosh GG, Anderson JJ, Milton I, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995;11:885-91.
17. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 1995;146:1161-9.
18. Gansauge S, Gansauge F, Ramadani M, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634-7.
19. Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger HG, Korc M. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology (in press).
20. Oertel JE, Heffess CS, Oertel YC. Pancreas. In: Sternberg SS, ed. Diagnostic surgical pathology. New York: Raven Press, 1989; 1057-93.
21. Beger HG, Büchler M. Duodenum preserving resection of the head of the pancreas in chronic pancreatitis with inflammatory mass in the head. World J Surg 1990;14:83-7.
22. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Büchler M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90:1352-60.
23. Kornmann M, Ishiwata T, Beger HG, Korc M. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene 1997;15:1417-24.
24. Friess H, Korc M, Büchler MW. Growth factors and growth factor receptors in chronic pancreatitis. In: Beger HG, Büchler MW, Schoenberg MH. eds. Cancer of the pancreas. Ulm, Germany: Universitätsverlag Ulm GmbH, 1996;143-50.
25. Furlanetto RW, Harwell SE, Frick KK. Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol Endocrinol 1994;8:510-7.
26. Won KA, Xiong Y, Beach D, Gilman MZ. Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci USA 1992;89:9910-4.
27. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK, Sutherland RL. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993;13:3577-87.
28. Winston JT, Pledger WJ. Growth factor regulation of cyclin D1 mRNA expression through protein synthesis-dependent and -independent mechanisms. Mol Biol Cell 1993;4:1133-44.
29. Niederau C, Niederau MC, Heintges T, Lüthen R. Epidemiology: relation between chronic pancreatitis and pancreatic carcinoma. In: Beger HG, Büchler MW, Schoenberg MH, eds. Cancer of the pancreas. Ulm, Germany: Universitätsverlag Ulm GmbH, 1996;9-15.
30. Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998;101:344-52.
31. Chu TM. Molecular diagnosis of pancreas carcinoma. J Clin Lab Anal 1997;225-31.